



# MEDICAMEN Organics Limited

Regd. & Corporate Office: 10, Community Centre No.2, Ashok Vihar Phase-II, Delhi-110052 (India)

Tel: 011-27430249, 27138171

E-mail: info@mediorganics.in | CIN No: L74899DL1995PLC066416 | GSTIN:07AABCM4302P1ZF

November 21, 2024

To,  
**National Stock Exchange of India Limited**  
**Listing & Compliance Department**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1,  
G Block, Bandra-Kurla Complex, Bandra  
Mumbai - 400051, India.

Company Symbol : **MEDIORG**  
Company ISIN : **INE0PE401018**

Dear Sir/Madam,

**Subject: Press Release - Medicamen Organics Secures ₹ 6.28 Cr Order for Povidone Iodine Solution**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith the copy of the Press Release pertains to secure the worth approximately Rs. 6.28 Cr (Rupees Six Crores & Twenty-Eight Lakhs Only) new orders for supply of **Povidone Iodine 10% SOL US EXT, FU200 ML**.

A copy of the press release is also uploaded on the Company's website i.e. [www.medicamenorganics.com](http://www.medicamenorganics.com)

We request you kindly acknowledge and take the same on your record.

Thanking You,

For **Medicamen Organics Limited**

**Bal Kishan Gupta**  
**Managing Director**  
**DIN: 00032772**

**Place: New Delhi**

**Encl.: as stated above**

---

## Works:

**Unit-1** : Plot No. 60, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | **GSTIN**: 05AABCM4302P1ZJ

**Unit-2** : Plot No. 61, Sector 6-A, I.I.E. SIDCUL, Haridwar- 249403 (U.K.) | **GSTIN**: 05AABCM4302P3ZH



## Medicamen Organics Secures ₹ 6.28 Cr Order for Povidone Iodine Solution

**Mumbai – November 21, 2024 – Medicamen Organics Limited (MOL) (NSE- MEDIORG)** one of the prominent players in the pharmaceutical sector, specializing in the development, manufacturing, and distribution of an extensive range of pharmaceutical dosage forms, has received a significant order valued at ₹ 6.28 Cr for the supply of **Povidone Iodine 10% Solution (US Extension), FU200 ML**.

The order involves 739,000 units of the antiseptic solution, which is widely used in healthcare settings for its reliable antiseptic properties. This achievement underscores MOL's strong reputation in delivering high-quality pharmaceutical products and meeting industry demand.

This order is expected to substantially contribute to the company's revenue in the upcoming quarters, further solidifying its position in the pharmaceutical market. This is a promising step for MOL as it continues to expand its presence in the healthcare sector.

**Commenting on the update, Mr. Bal Kishan Gupta, Managing Director said,** "We are pleased to secure this significant order for Povidone Iodine 10% Solution, which reinforces the trust our customers place in Medicamen Organics Limited. This order is expected to make a substantial contribution to our revenue in the coming quarters and is a reflection of our relentless efforts to deliver high-quality pharmaceutical products.

Our strong order pipeline further underscores the growing recognition of our capabilities and commitment to meeting market needs. We remain focused on leveraging these opportunities to drive sustainable growth and strengthen our position in the pharmaceutical industry."

### About Medicamen Organics Limited:

Medicamen Organics Limited stands out as a prominent player in the pharmaceutical sector, specializing in the development, manufacturing, and distribution of an extensive range of pharmaceutical dosage forms. These include Tablets, Capsules, Oral Liquids, Ointments, Gels, Syrups, Suspensions, and Dry Powders. The company's diverse offerings serve both state and central government institutions as well as private entities, operating as a contract and third-party manufacturer

The company has two WHO GMP-approved manufacturing facilities located in Haridwar, Uttarakhand, covering an area of 21,536 sq. ft. These facilities feature cutting-edge infrastructure and in-house testing laboratories. A team of skilled and experienced professionals supports a streamlined production process, maintaining consistent quality.

Focused on global expansion, Medicamen Organics has made significant strides in establishing a direct international presence. Notably, during fiscal years 2023 and 2024, the company exported products directly to Burundi, East Africa. Operating under a proven B2B contract manufacturing model, the company's products are distributed not only throughout India but also in African, CIS, and Southeast Asian countries, including Congo, Benin, Cameg, Togo, Senegal, Burkina Faso, the Philippines, Myanmar, Mozambique, Kyrgyzstan, and Kenya.

The company's core business model revolves around B2B contract manufacturing, partnering with third-party pharmaceutical companies to market and sell its products. Medicamen Organics also engages actively in government tenders, supplying products to government hospitals, departments, PSUs, and armed forces.

The Company got listed on NSE Emerge in June 28, 2024.

For FY24, the Company has reported Total Income of ₹ 25.29 Cr, with EBITDA of ₹ 4.76 Cr & PAT of ₹ 2.62 Cr.

#### Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

#### For Further Information Please Contact Corporate Communication Advisor



**Kirin Advisors Private Limited**

Sunil Mudgal – Director

[sunil@kirinadvisors.com](mailto:sunil@kirinadvisors.com)

+91 98692 75849

[www.kirinadvisors.com](http://www.kirinadvisors.com)